EyePoint (EYPT) Non-Current Deffered Revenue (2011 - 2024)
EyePoint (EYPT) reported Non-Current Deffered Revenue of $10.9 million for Q4 2024, down 47.55% on a YoY basis from $20.7 million in Q1 2024, and down 3.39% sequentially from $11.2 million in Q3 2024.
EyePoint (EYPT) Non-Current Deffered Revenue (2011 - 2024) Analysis & Trends
EyePoint (EYPT) has 12 years of Non-Current Deffered Revenue data on file, last reported at $10.9 million in Q4 2024.
- For the quarter ending Q4 2024, Non-Current Deffered Revenue fell 47.55% year-over-year to $10.9 million; the trailing twelve-month figure through Dec 2024 stood at $10.9 million (down 47.55% YoY), and the FY2024 full-year result was $10.9 million, down 47.55% from the prior year.
- Non-Current Deffered Revenue retreated to $10.9 million in Q4 2024, from $11.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $44.0 million in Q2 2023 to a low of $10.9 million in Q4 2024.
- A 5-year average of $16.9 million and a median of $14.3 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue soared 212.87% in 2023 and tumbled 73.47% in 2024, its largest moves.
- Tracing EYPT's Non-Current Deffered Revenue over 5 years: stood at $15.6 million in 2020, then slipped by 6.76% to $14.6 million in 2021, then retreated by 6.89% to $13.6 million in 2022, then soared by 52.63% to $20.7 million in 2023, then slumped by 47.55% to $10.9 million in 2024.
- Business Quant data shows EYPT's Non-Current Deffered Revenue at $10.9 million in Q4 2024, $11.2 million in Q3 2024, and $11.7 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 10.85 Mn |
| Sep 30, 2024 | 11.23 Mn |
| Jun 30, 2024 | 11.68 Mn |
| Mar 31, 2024 | 12.11 Mn |
| Dec 31, 2023 | 20.69 Mn |
| Sep 30, 2023 | 32.34 Mn |
| Jun 30, 2023 | 44.02 Mn |
| Mar 31, 2023 | 13.27 Mn |
| Dec 31, 2022 | 13.56 Mn |
| Sep 30, 2022 | 13.80 Mn |
| Jun 30, 2022 | 14.07 Mn |
| Mar 31, 2022 | 14.30 Mn |
| Dec 31, 2021 | 14.56 Mn |
| Sep 30, 2021 | 14.79 Mn |
| Jun 30, 2021 | 15.13 Mn |
| Mar 31, 2021 | 15.35 Mn |
| Dec 31, 2020 | 15.62 Mn |
| Dec 31, 2017 | 42,000.00 |
| Sep 30, 2017 | 47,000.00 |
| Jun 30, 2017 | 51,000.00 |